Drugs / PF-06412562
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03686501 | Sep 2018 → Mar 2019 | — | Invicro | Completed | No outcome recorded |
| Phase 18 trials · 1 missed | ||||||
| Phase 1 | NCT03665454 | Sep 2018 → Mar 2019 | Parkinson disease | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03181841 | May → Dec 2017 | — | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT02418819 | Apr 2015 → Oct 2016 | schizophrenia | Pfizer | Completed | Missed primary |
| Phase 1 | NCT02306876 | Jan 2015 → Jun 2016 | — | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02124213 | Sep → Oct 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02201511 | Sep → Oct 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02006290 | Mar → Aug 2014 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01959594 | Nov 2013 → Mar 2014 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01914796 Comparator | Aug → Dec 2013 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF 06412562 | “OBJECTIVE: To determine the feasibility and safety of the selective D1/D5 dopamine partial agonist PF 06412562 in advPD.” PMID 32986682 ↗ 2020 |
| Action | Activate | “PF-06412562, a selective D1/D5R partial agonist” PMID 32055822 ↗ May 2020 |
| Route | Oral | “PF-06412562 given orally to healthy volunteers” NCT01914796 ↗ |